Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 9:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,525 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 0.9% NaCl solution Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 6, 2026, 9:57 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults

NCT02421367
View directory record Official record
Conditions
Dengue
Interventions
TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
20 Years to 49 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 6, 2026, 9:57 PM EDT
Recruiting Phase 4 Interventional

Multifidus Cervicis Plane Block Vs. Sham Block For Posterior Cervical Spine Fusion Surgery

NCT05996133
View directory record Official record
Conditions
Cervical Spine Fusion
Interventions
Bupivacaine Hcl 0.25% Inj, Normal saline
Drug · Other
Lead sponsor
Hartford Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 6, 2026, 9:57 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department

NCT02417298
View directory record Official record
Conditions
Pain, Sickle Cell Disorder
Interventions
Normal saline, Ketamine
Drug
Lead sponsor
Billy Sin
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 6, 2026, 9:57 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

NCT04659863
View directory record Official record
Conditions
Familial Hypercholesterolemia - Homozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 6, 2026, 9:57 PM EDT
Completed Phase 2 Interventional Results available

DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis

NCT03825315
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
DAXI 80 U, DAXI 120 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Tucson, Arizona • Carmichael, California • Castro Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 6, 2026, 9:57 PM EDT
Terminated Phase 4 Interventional

Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease

NCT01738243
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Hyaluronic Acid Gel injection, Saline injection
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Sep 6, 2026, 9:57 PM EDT
Terminated Phase 2 Interventional Results available

High Dose Intravenous Ascorbic Acid in Severe Sepsis

NCT02734147
View directory record Official record
Conditions
Sepsis
Interventions
Ascorbic Acid, Normal Saline
Drug · Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 6, 2026, 9:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Preoperative Skin Preparation Evaluation

NCT00636480
View directory record Official record
Conditions
Topical Antisepsis
Interventions
Chlorhexidine gluconate, ChloraPrep One Step, Sterile saline
Drug
Lead sponsor
C. R. Bard
Industry
Eligibility
16 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 6, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

NCT04468958
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Wichita, Kansas • Syracuse, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 6, 2026, 9:57 PM EDT
Recruiting Phase 3 Interventional

SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)

NCT06945315
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction
Interventions
RALP (Robotic-assisted radical prostatectomy), SAFE (Saline assisted fascial engorgement)
Procedure · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Sep 6, 2026, 9:57 PM EDT
Completed Phase 2 Interventional Results available

Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: A Pilot and Feasibility Study

NCT02840097
View directory record Official record
Conditions
Brain Injuries, Wounds and Injuries, Hemorrhage
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Daniel Nishijima, MD, MAS
Other
Eligibility
Up to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Sacramento, California • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 6, 2026, 9:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Berinert (C1INH) vs Placebo for DGF/IRI

NCT04696146
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Berinert, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 6, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects

NCT01648179
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 (mesylate salt) Powder for Injection, GSK1322322 (freebase) tablets, GSK1322322 (mesylate salt) Powder for Oral Solution, GSK1322322 (freebase) tablets FED
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 6, 2026, 9:57 PM EDT
Recruiting Phase 2 Interventional

Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites

NCT06812390
View directory record Official record
Conditions
Cirrhosis, Ascites Hepatic
Interventions
Albumin infusion (25% albumin), Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Anahita Rabiee MD MHS
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 6, 2026, 9:57 PM EDT
Completed Phase 1 Interventional Results available

Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms

NCT02158039
View directory record Official record
Conditions
Neoplasms, Cystic, Mucinous, and Serous
Interventions
Ethanol, Lidocaine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 6, 2026, 9:57 PM EDT
Completed Phase 3 Interventional

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

NCT04799249
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions
Trilaciclib, Placebo, Gemcitabine, Carboplatin
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 6, 2026, 9:57 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Peripheral Nerve Blocks for Major Lower Extremity Amputations

NCT03174782
View directory record Official record
Conditions
Postoperative Pain
Interventions
Bupivacaine, Saline Solution
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 6, 2026, 9:57 PM EDT
Completed Phase 2 Interventional Results available

Recombinant Human Prolactin for Lactation Induction

NCT00181610
View directory record Official record
Conditions
Lactation
Interventions
Recombinant Human Prolactin, Recombinant human prolactin, Normal Saline
Drug · Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Sep 6, 2026, 9:57 PM EDT
Recruiting Phase 2 Interventional

Antibiotic Tumescent For Chronic Wounds

NCT06327113
View directory record Official record
Conditions
Non-healing Wound
Interventions
CeFAZolin Injectable Solution
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 6, 2026, 9:57 PM EDT
Terminated Phase 4 Interventional Results available

Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation

NCT03247413
View directory record Official record
Conditions
Neuritis, Radiofrequency Ablation
Interventions
Dexamethasone 4 mg/ml, Normal saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 6, 2026, 9:57 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty

NCT02713178
View directory record Official record
Conditions
Pain
Interventions
bupivacaine liposome injectable suspension, Placebo
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Mobile, Alabama • Englewood, Colorado • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 6, 2026, 9:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clostridium Difficile Vaccine Efficacy Trial

NCT03090191
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Clostridium difficile vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
17,535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
220
States / cities
Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 145 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 6, 2026, 9:57 PM EDT
Completed Not applicable Interventional

Local Infiltration Analgesia for Hip Arthroscopy

NCT01454518
View directory record Official record
Conditions
Pain
Interventions
Infiltration of local anesthetic, Normal Saline Injection
Procedure
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2013 · Synced Sep 6, 2026, 9:57 PM EDT